GSK plc
GSK.N- Latest Trade
- trading higher34.93USD
- 0.86
- 2.52%
- As of Mar 21 2023. Values delayed up to 15 minutes
- Today's Range
- 34.39 - 34.94
- 52 Week Range
- 28.47 - 46.97
- Previous Close
- 34.07
- Open
- 34.54
- Volume
- 534,581.00
- 3 Month Average Trading Volume
- 75.68
- Shares Out (Mil)
- 4,034.34
- Market Cap
- 69,447.84
- Forward P/E
- 9.30
- Dividend Yield
- 4.07
Key Statistics
2.80 mean rating - 5 analysts
- P/E Excl. Extra Items (TTM)
- 11.92
- Price To Sales (TTM)
- 1.95
- Price To Book (Quarterly)
- 5.33
- Price To Cash Flow (Per Share TTM)
- 7.90
- Total Debt/Total Equity (Quarterly)
- 198.03
- Long Term Debt/Equity (Quarterly)
- 160.74
- Return On Investment (TTM)
- 11.31
- Return On Equity (TTM)
- 7.07
2021 (millions USD)
About GSK plc (GSK.N)
Company Information
GSK plc is a global biopharma company. The Company makes vaccines and specialty medicines to prevent and treat disease. Its segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed a new monoclonal antibody treatment for COVID-19. Its product areas include vaccines, specialty medicines, and general medicines. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions, including the chronic autoimmune condition lupus, respiratory disease, and human immunodeficiency virus (HIV). Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics and medicines for skin diseases. It has a global network of about 12 vaccines manufacturing sites.
Address
980 Great West RoadBRENTFORD,
TW8 9GS
United Kingdom
Industry
Biotechnology & Drugs
Executive Leadership
- Jonathan Richard Symonds
- Independent Non-Executive Chairman of the Board
- Emma N. Walmsley
- Chief Executive Officer, Executive Director
- Iain James Mackay
- Chief Financial Officer, Executive Director
- Roger G. Connor
- President - Vaccines and Global Health
- Brian McNamara
- Chief Executive Officer - GSK Consumer Healthcare
- Regis Simard
- President - Pharmaceutical Supply Chain
- Phil C. Thomson
- President - Global Affairs
- Deborah Waterhouse
- Chief Executive Officer - ViiV Healthcare
- Diana Conrad
- Chief People Officer
- James Ford
- Senior Vice President, Group General Counsel, Legal and Compliance
- Sally Jackson
- Senior Vice President - Global Communications and CEO Office
- Shobie Ramakrishnan
- Chief Digital and Technology Officer
- Tony Wood
- Chief Scientific Officer
- Luke Miels
- Chief Commercial Officer
- David S. Redfern
- Chief Strategy Officer
- Victoria Anne Whyte
- Company Secretary
- Hal V. Barron
- Non-Executive Non-independent Director
- Elizabeth McKee Anderson
- Non-Executive Independent Director
- Charles A. Bancroft
- Senior Non-Executive Independent Director
- Harry C. Dietz
- Non-Executive Independent Director, Scientific and Medical Expert
- Jesse Goodman
- Non-Executive Independent Director and Scientific and Medical Expert
- Urs Rohner
- Non-Executive Independent Director
- Vishal Sikka
- Non-Executive Independent Director
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,973.80 | 0.27% |
| Copper | 763.20 | 0.64% |
| Brent Crude Oil | 74.38 | 0.80% |
| CBOT Soybeans | 1,486.25 | 0.02% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,951.57 | 0.89% |
| Euro STOXX 50 | 4,179.05 | 1.45% |
| FTSE 100 | 7,504.23 | 1.36% |
| Nikkei 225 | 26,945.67 | 1.42% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes